SGOL1 Antibody

What are the validated applications for SGOL1 antibodies in research?

SGOL1 antibodies have been validated for multiple experimental applications including Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF), and Enzyme-Linked Immunosorbent Assay (ELISA). The optimal working dilutions vary by application: WB (1:500-1:2000), IHC (1:100-1:300), ELISA (1:20000), and ICC/IF (1:50-200). For reliable results, researchers should optimize these dilutions for their specific experimental conditions and sample types .

How should SGOL1 antibodies be stored to maintain optimal activity?

For long-term storage, SGOL1 antibodies should be kept at -20°C for up to one year. For frequent use and short-term storage (up to one month), store at 4°C. Avoid repeated freeze-thaw cycles as they can compromise antibody integrity and binding efficacy. Most commercial SGOL1 antibodies are supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide to enhance stability .

What is the molecular weight of SGOL1 protein and what should I expect on Western blots?

When performing Western blot analysis with SGOL1 antibodies, the observed molecular weight is typically around 72 kDa, while the calculated molecular weight based on amino acid sequence is 64.19 kDa. This discrepancy is common and may be attributed to post-translational modifications or the presence of isoforms. When validating a new SGOL1 antibody, performing Western blots with positive control cell lines like HeLa cells is recommended .

What sample preparation protocols are most effective for SGOL1 detection in tissue samples?

For optimal SGOL1 detection in paraffin-embedded tissue sections, implement antigen retrieval using Tris-EDTA buffer at pH 9.0. Antibody dilution of 1:200 is generally effective when incubated overnight at 4°C, followed by detection with a secondary antibody at 1:200 dilution for 45 minutes at room temperature. For human tissues such as tonsil samples, this protocol has yielded clear staining patterns. When working with other tissue types, validation of staining specificity using positive and negative controls is crucial .

How can I confirm the specificity of SGOL1 antibody staining in my experiments?

To confirm antibody specificity, employ multiple validation approaches. First, use blocking peptides (derived from the immunogen sequence, location 271-320 of human SGOL1) to demonstrate signal elimination when the antibody is pre-incubated with the peptide. Second, perform parallel experiments with alternative antibodies recognizing different epitopes of SGOL1. Third, include known positive (e.g., HeLa cells) and negative tissue/cell controls. For advanced validation, SGOL1 knockdown or knockout samples provide definitive evidence of staining specificity .

Can SGOL1 antibodies be used for cross-species applications beyond humans?

While many commercial SGOL1 antibodies are validated for human, mouse, and rat samples, cross-reactivity with other species requires empirical testing. Sequence homology analysis between human SGOL1 and the target species can provide preliminary indication of potential cross-reactivity. For untested species such as porcine tissues, researchers should perform validation experiments including Western blot with appropriate controls. Some antibody suppliers offer innovator programs that provide incentives for researchers who validate antibodies in new species applications .

How should researchers interpret variations in SGOL1 expression patterns between different cell types?

SGOL1 expression can vary significantly across cell types due to its role in cell cycle regulation and chromosome segregation. When interpreting expression data, consider the proliferative status of cells, as SGOL1 expression is typically higher in rapidly dividing cells. In cancer research, elevated SGOL1 expression often correlates with adverse clinicopathological parameters and unfavorable prognosis, as demonstrated in clear cell renal cell carcinoma (ccRCC). Compare expression levels to established baselines for the specific cell type or tissue under investigation, and correlate with other cell cycle markers to contextualize the findings .

What are common technical challenges when using SGOL1 antibodies and how can they be addressed?

When troubleshooting, remember that SGOL1 is involved in the cell cycle, so expression and localization may vary depending on cell cycle stage. Flow cytometry with cell cycle analysis can help interpret apparent inconsistencies in SGOL1 detection .

How can SGOL1 antibodies be employed in studying the tumor microenvironment and immune infiltration?

SGOL1 expression has been correlated with immune cell infiltration in tumors, particularly in ccRCC. Researchers can use SGOL1 antibodies in multiplex immunofluorescence or immunohistochemistry to simultaneously detect SGOL1 and immune cell markers. This approach allows for spatial analysis of SGOL1-expressing tumor cells in relation to tumor-infiltrating lymphocytes. Studies have shown that high SGOL1 expression correlates with increased infiltration of regulatory T cells (Tregs), T helper cells, and macrophages in the tumor microenvironment, suggesting its potential role in immune evasion mechanisms .

What methodologies are recommended for investigating SGOL1's role in cancer progression and metastasis?

To investigate SGOL1's role in cancer progression, implement a multi-faceted approach:

• Expression analysis: Use SGOL1 antibodies for IHC on tissue microarrays containing primary tumors, metastatic lesions, and normal adjacent tissues to establish expression patterns

• Functional studies: Employ SGOL1 knockdown/overexpression combined with proliferation assays (MTT, EdU staining), migration assays (wound healing), and invasion assays (Transwell)

• Mechanistic studies: Use co-immunoprecipitation with SGOL1 antibodies to identify protein interaction partners, followed by Western blotting to analyze downstream pathway activation (p53 pathway, cell cycle regulators)

• In vivo models: Utilize xenograft models with SGOL1-modulated cell lines and analyze tumor growth, metastasis, and survival rates

Research has demonstrated that SGOL1 promotes ccRCC cell proliferation, migration, and invasion in vitro, suggesting its oncogenic potential .

How can SGOL1 antibodies be used for biomarker development in cancer diagnostics and prognostics?

For biomarker development, SGOL1 antibodies can be utilized in several approaches:

• Tissue-based assays: Standardize IHC protocols for SGOL1 detection in clinical samples and establish scoring systems correlated with patient outcomes. Multivariate logistic regression and nomogram calibration have suggested SGOL1 as an independent prognostic predictor in ccRCC.

• Combinatorial biomarker panels: Combine SGOL1 with other markers (immune checkpoints such as PD-L1, CD276, TIGIT) for improved predictive accuracy, as SGOL1 expression has been positively correlated with immune checkpoint inhibitor expression.

• Liquid biopsy applications: Explore detection of SGOL1 in circulating tumor cells or exosomes as minimally invasive prognostic tools.

• Predictive biomarkers for therapy: Evaluate SGOL1 expression as a predictor of response to immunotherapies, as high SGOL1 expression correlates with increased expression of immune checkpoint molecules .

What is known about SGOL1's role in chromosome segregation and how can researchers investigate this function?

SGOL1 (Shugoshin-1) is essential for accurate chromosome segregation during mitosis and meiosis. To investigate this function, researchers should:

• Use immunofluorescence with SGOL1 antibodies to visualize its localization to centromeres and kinetochores during different cell cycle phases

• Perform live-cell imaging with fluorescently tagged SGOL1 to track its dynamics during mitosis

• Analyze sister chromatid cohesion after SGOL1 depletion using chromosome spreads and fluorescence in situ hybridization

• Assess the interaction between SGOL1 and PP2A (protein phosphatase 2A) through co-immunoprecipitation, as this interaction is crucial for protecting centromeric cohesion

Functional enrichment analysis reveals that SGOL1 is associated with biological processes including nuclear division, regulation of cell cycle phase transition, sister chromatid segregation, and molecular functions such as tubulin binding and microtubule binding .

How is SGOL1 involved in signaling pathways related to cancer progression?

SGOL1's involvement in cancer progression is linked to several signaling pathways:

• Cell cycle regulation: SGOL1 participates in chromosomal region organization, microtubule function, and kinetochore assembly. Dysregulation leads to chromosomal instability and aneuploidy, common features in cancer.

• P53 signaling pathway: KEGG pathway analysis reveals that SGOL1 and its correlated genes are significantly involved in the p53 signaling pathway, which regulates cell cycle arrest, apoptosis, and DNA repair.

• DNA replication and repair: SGOL1 is associated with homologous recombination and DNA replication pathways, suggesting a role in genomic stability maintenance.

• Immunomodulatory functions: SGOL1 expression correlates with increased Treg infiltration and immune checkpoint upregulation, potentially contributing to an immunosuppressive tumor microenvironment.

• Non-coding RNA regulatory network: A potential SNHG17/PVT1/ZMIZ1-AS1-miR-23b-3p-SGOL1 axis has been identified in ccRCC carcinogenesis and progression .

What experimental approaches are recommended for investigating the relationship between SGOL1 and immune checkpoint inhibitor efficacy?

To investigate SGOL1's relationship with immune checkpoint inhibitor efficacy:

• Correlation analysis: Perform multiplex IHC or flow cytometry to quantify the co-expression of SGOL1 with immune checkpoint molecules (PD-L1, TIGIT, PDCD1, LAG3, CTLA4) in tumor samples.

• In vitro co-culture systems: Establish co-culture systems with SGOL1-modulated tumor cells and immune cells to assess changes in T-cell activation, exhaustion, and cytotoxicity.

• In vivo models: Use syngeneic mouse models with SGOL1-knocked down or overexpressed tumors to evaluate response to immune checkpoint blockade therapy.

• Clinical correlation studies: Retrospectively analyze SGOL1 expression in tumor samples from patients treated with immune checkpoint inhibitors to identify correlations with treatment response and survival outcomes.

Research has shown that high SGOL1 expression is associated with elevated expression of multiple immune checkpoint inhibitors, suggesting that SGOL1 levels might predict immunotherapy response in cancers like ccRCC .